STING1 and neoplasm: In tumours, STING pathway activation leads to interferon-β production and T-cell response.62 Cyclic dinucleotides have been found to act as immune adjuvants by activating STING, in turn stimulating a proinflammatory immune response;68 Phase 1 trials of two intratumoural STING agonists, ADU-S100 and MK-1454, are ongoing.69–71